Piper Sandler Raises Edwards Lifesciences (NYSE:EW) Price Target to $93.00

Edwards Lifesciences (NYSE:EW) had its price target boosted by Piper Sandler from $91.00 to $93.00 in a research note published on Wednesday, Anlyst Ratings reports. The firm currently has an overweight rating on the medical research company’s stock. Piper Sandler also issued estimates for Edwards Lifesciences’ Q1 2022 earnings at $0.59 EPS, Q2 2022 earnings at $0.62 EPS and Q3 2022 earnings at $0.61 EPS.

EW has been the subject of a number of other research reports. Raymond James upped their price target on Edwards Lifesciences from $83.00 to $88.00 and gave the stock an outperform rating in a research report on Friday, July 24th. Wolfe Research started coverage on Edwards Lifesciences in a research report on Friday, September 11th. They issued an underperform rating for the company. Canaccord Genuity upped their price target on Edwards Lifesciences from $86.00 to $89.00 and gave the stock a buy rating in a research report on Friday, July 24th. Oppenheimer started coverage on Edwards Lifesciences in a research report on Monday, July 13th. They issued a buy rating and a $93.00 price target for the company. Finally, SVB Leerink upped their price target on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an outperform rating in a research report on Monday, October 12th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $84.77.

Edwards Lifesciences stock opened at $85.33 on Wednesday. The stock has a market cap of $53.05 billion, a PE ratio of 73.35, a price-to-earnings-growth ratio of 2.90 and a beta of 0.90. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.24 and a current ratio of 3.08. Edwards Lifesciences has a one year low of $51.51 and a one year high of $87.79. The stock has a fifty day moving average of $82.05 and a 200 day moving average of $84.50.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.19. The company had revenue of $925.00 million during the quarter, compared to analysts’ expectations of $782.90 million. Edwards Lifesciences had a return on equity of 29.11% and a net margin of 17.21%. As a group, sell-side analysts predict that Edwards Lifesciences will post 1.86 EPS for the current fiscal year.

In other news, VP Larry L. Wood sold 10,698 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $78.40, for a total value of $838,723.20. Following the completion of the sale, the vice president now directly owns 374,181 shares of the company’s stock, valued at approximately $29,335,790.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Scott B. Ullem sold 33,150 shares of the firm’s stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $83.81, for a total value of $2,778,301.50. Following the completion of the sale, the chief financial officer now directly owns 60,264 shares of the company’s stock, valued at $5,050,725.84. The disclosure for this sale can be found here. Over the last three months, insiders have sold 429,773 shares of company stock valued at $34,576,732. 1.48% of the stock is owned by corporate insiders.

Several large investors have recently bought and sold shares of the company. San Francisco Sentry Investment Group CA raised its holdings in shares of Edwards Lifesciences by 536.2% in the second quarter. San Francisco Sentry Investment Group CA now owns 369 shares of the medical research company’s stock worth $26,000 after buying an additional 311 shares during the period. Savior LLC raised its holdings in shares of Edwards Lifesciences by 243.6% in the second quarter. Savior LLC now owns 378 shares of the medical research company’s stock worth $26,000 after buying an additional 268 shares during the period. Gemmer Asset Management LLC raised its holdings in shares of Edwards Lifesciences by 205.6% in the second quarter. Gemmer Asset Management LLC now owns 382 shares of the medical research company’s stock worth $26,000 after buying an additional 257 shares during the period. Sun Life Financial INC raised its holdings in shares of Edwards Lifesciences by 206.6% in the second quarter. Sun Life Financial INC now owns 374 shares of the medical research company’s stock worth $26,000 after buying an additional 252 shares during the period. Finally, Procyon Private Wealth Partners LLC raised its holdings in shares of Edwards Lifesciences by 276.3% in the first quarter. Procyon Private Wealth Partners LLC now owns 143 shares of the medical research company’s stock worth $27,000 after buying an additional 105 shares during the period. 79.70% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Featured Story: What does cost of debt say about a company’s financial health?

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.